Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Space & Defense Innovation ETF (ARKX) vs Cassava Sciences Inc (FLNA) Price & Performance

ARK Space & Defense Innovation ETF
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

ARK Space & Defense Innovation ETF vs Cassava Sciences Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $31.76, while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ARKXFLNA
Sector
Sector/ThematicHealth
52-Week High
$37.74$4.64
52-Week Low
$24.97$1.16
Market Cap
$57.49M
Enterprise Value
-$29.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Space & Defense Innovation ETF

ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).

ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

About ARK Space & Defense Innovation ETF

ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.

Read more on ARKX

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA